The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global GLP-1 Agonist Market Research Report 2024

Global GLP-1 Agonist Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1745158

No of Pages : 90

Ask Your Query

Synopsis
GLP-1 is a polypeptide hormone secreted by the intestine after being stimulated by food. It can stimulate the pancreatic beta cells to secrete insulin and participate in the regulation of blood sugar balance in the human body. However, natural GLP-1 is easily degraded by dipeptidyl peptidase in vivo and loses its activity. In order to make GLP-1 better for clinical application, drug developers have modified its structure and developed a series of GLP-1 receptor agonists. GLP-1 receptor agonists can exert the same biological effects as natural GLP-1, and can also avoid being degraded and inactivated, thereby prolonging the action time.

Global GLP-1 Agonist market is projected to reach US$ 44730 million in 2029, increasing from US$ 20600 million in 2022, with the CAGR of 16.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole GLP-1 Agonist market research.

Key manufacturers engaged in the GLP-1 Agonist industry include Novo Nordisk, AstraZeneca, Sanofi, GSK, Eli Lilly, Zealand Pharma A/S, hansoh and BENEMAE, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of GLP-1 Agonist were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole GLP-1 Agonist market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global GLP-1 Agonist market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Novo Nordisk
  • AstraZeneca
  • Sanofi
  • GSK
  • Eli Lilly
  • Zealand Pharma A/S
  • hansoh
  • BENEMAE

Segment by Type

  • Long-Acting Drug
  • Short-Acting Drug

Segment by Application

  • Diabetes
  • Obesity
  • Nonalcoholic Fatty Liver Disease
  • Metabolic Disorder
  • Alzheimer's Disease
  • Other

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The GLP-1 Agonist report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 GLP-1 Agonist Market Overview
1.1 Product Overview and Scope of GLP-1 Agonist
1.2 GLP-1 Agonist Segment by Type
1.2.1 Global GLP-1 Agonist Market Value Comparison by Type (2023-2029)
1.2.2 Long-Acting Drug
1.2.3 Short-Acting Drug
1.3 GLP-1 Agonist Segment by Application
1.3.1 Global GLP-1 Agonist Market Value by Application: (2023-2029)
1.3.2 Diabetes
1.3.3 Obesity
1.3.4 Nonalcoholic Fatty Liver Disease
1.3.5 Metabolic Disorder
1.3.6 Alzheimer's Disease
1.3.7 Other
1.4 Global GLP-1 Agonist Market Size Estimates and Forecasts
1.4.1 Global GLP-1 Agonist Revenue 2018-2029
1.4.2 Global GLP-1 Agonist Sales 2018-2029
1.4.3 Global GLP-1 Agonist Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 GLP-1 Agonist Market Competition by Manufacturers
2.1 Global GLP-1 Agonist Sales Market Share by Manufacturers (2018-2023)
2.2 Global GLP-1 Agonist Revenue Market Share by Manufacturers (2018-2023)
2.3 Global GLP-1 Agonist Average Price by Manufacturers (2018-2023)
2.4 Global GLP-1 Agonist Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of GLP-1 Agonist, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of GLP-1 Agonist, Product Type & Application
2.7 GLP-1 Agonist Market Competitive Situation and Trends
2.7.1 GLP-1 Agonist Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest GLP-1 Agonist Players Market Share by Revenue
2.7.3 Global GLP-1 Agonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 GLP-1 Agonist Retrospective Market Scenario by Region
3.1 Global GLP-1 Agonist Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global GLP-1 Agonist Global GLP-1 Agonist Sales by Region: 2018-2029
3.2.1 Global GLP-1 Agonist Sales by Region: 2018-2023
3.2.2 Global GLP-1 Agonist Sales by Region: 2024-2029
3.3 Global GLP-1 Agonist Global GLP-1 Agonist Revenue by Region: 2018-2029
3.3.1 Global GLP-1 Agonist Revenue by Region: 2018-2023
3.3.2 Global GLP-1 Agonist Revenue by Region: 2024-2029
3.4 North America GLP-1 Agonist Market Facts & Figures by Country
3.4.1 North America GLP-1 Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America GLP-1 Agonist Sales by Country (2018-2029)
3.4.3 North America GLP-1 Agonist Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe GLP-1 Agonist Market Facts & Figures by Country
3.5.1 Europe GLP-1 Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe GLP-1 Agonist Sales by Country (2018-2029)
3.5.3 Europe GLP-1 Agonist Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific GLP-1 Agonist Market Facts & Figures by Country
3.6.1 Asia Pacific GLP-1 Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific GLP-1 Agonist Sales by Country (2018-2029)
3.6.3 Asia Pacific GLP-1 Agonist Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America GLP-1 Agonist Market Facts & Figures by Country
3.7.1 Latin America GLP-1 Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America GLP-1 Agonist Sales by Country (2018-2029)
3.7.3 Latin America GLP-1 Agonist Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa GLP-1 Agonist Market Facts & Figures by Country
3.8.1 Middle East and Africa GLP-1 Agonist Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa GLP-1 Agonist Sales by Country (2018-2029)
3.8.3 Middle East and Africa GLP-1 Agonist Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global GLP-1 Agonist Sales by Type (2018-2029)
4.1.1 Global GLP-1 Agonist Sales by Type (2018-2023)
4.1.2 Global GLP-1 Agonist Sales by Type (2024-2029)
4.1.3 Global GLP-1 Agonist Sales Market Share by Type (2018-2029)
4.2 Global GLP-1 Agonist Revenue by Type (2018-2029)
4.2.1 Global GLP-1 Agonist Revenue by Type (2018-2023)
4.2.2 Global GLP-1 Agonist Revenue by Type (2024-2029)
4.2.3 Global GLP-1 Agonist Revenue Market Share by Type (2018-2029)
4.3 Global GLP-1 Agonist Price by Type (2018-2029)
5 Segment by Application
5.1 Global GLP-1 Agonist Sales by Application (2018-2029)
5.1.1 Global GLP-1 Agonist Sales by Application (2018-2023)
5.1.2 Global GLP-1 Agonist Sales by Application (2024-2029)
5.1.3 Global GLP-1 Agonist Sales Market Share by Application (2018-2029)
5.2 Global GLP-1 Agonist Revenue by Application (2018-2029)
5.2.1 Global GLP-1 Agonist Revenue by Application (2018-2023)
5.2.2 Global GLP-1 Agonist Revenue by Application (2024-2029)
5.2.3 Global GLP-1 Agonist Revenue Market Share by Application (2018-2029)
5.3 Global GLP-1 Agonist Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Corporation Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk GLP-1 Agonist Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Novo Nordisk GLP-1 Agonist Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca GLP-1 Agonist Sales, Revenue and Gross Margin (2018-2023)
6.2.4 AstraZeneca GLP-1 Agonist Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi GLP-1 Agonist Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sanofi GLP-1 Agonist Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 GSK
6.4.1 GSK Corporation Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK GLP-1 Agonist Sales, Revenue and Gross Margin (2018-2023)
6.4.4 GSK GLP-1 Agonist Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Eli Lilly
6.5.1 Eli Lilly Corporation Information
6.5.2 Eli Lilly Description and Business Overview
6.5.3 Eli Lilly GLP-1 Agonist Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Eli Lilly GLP-1 Agonist Product Portfolio
6.5.5 Eli Lilly Recent Developments/Updates
6.6 Zealand Pharma A/S
6.6.1 Zealand Pharma A/S Corporation Information
6.6.2 Zealand Pharma A/S Description and Business Overview
6.6.3 Zealand Pharma A/S GLP-1 Agonist Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Zealand Pharma A/S GLP-1 Agonist Product Portfolio
6.6.5 Zealand Pharma A/S Recent Developments/Updates
6.7 hansoh
6.6.1 hansoh Corporation Information
6.6.2 hansoh Description and Business Overview
6.6.3 hansoh GLP-1 Agonist Sales, Revenue and Gross Margin (2018-2023)
6.4.4 hansoh GLP-1 Agonist Product Portfolio
6.7.5 hansoh Recent Developments/Updates
6.8 BENEMAE
6.8.1 BENEMAE Corporation Information
6.8.2 BENEMAE Description and Business Overview
6.8.3 BENEMAE GLP-1 Agonist Sales, Revenue and Gross Margin (2018-2023)
6.8.4 BENEMAE GLP-1 Agonist Product Portfolio
6.8.5 BENEMAE Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 GLP-1 Agonist Industry Chain Analysis
7.2 GLP-1 Agonist Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 GLP-1 Agonist Production Mode & Process
7.4 GLP-1 Agonist Sales and Marketing
7.4.1 GLP-1 Agonist Sales Channels
7.4.2 GLP-1 Agonist Distributors
7.5 GLP-1 Agonist Customers
8 GLP-1 Agonist Market Dynamics
8.1 GLP-1 Agonist Industry Trends
8.2 GLP-1 Agonist Market Drivers
8.3 GLP-1 Agonist Market Challenges
8.4 GLP-1 Agonist Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock